León-Espinoza C, López-Mozos F, Marti-Obiol R, Garces-Albir M, Ortega-Serrano J. “Magic” of our gastric cancer results on perioperative chemotherapy. World J Gastrointest Pathophysiol 2016; 7(3): 283-287 [PMID: 27574566 DOI: 10.4291/wjgp.v7.i3.283]
Corresponding Author of This Article
Marina Garces-Albir, MD, PhD, Department of Digestive and General Surgery, Hospital Clínico Universitario de Valencia, Avd. Blasco Ibañez, 17, 46010 Valencia, Spain. garalma@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Aug 15, 2016; 7(3): 283-287 Published online Aug 15, 2016. doi: 10.4291/wjgp.v7.i3.283
“Magic” of our gastric cancer results on perioperative chemotherapy
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano
Carlos León-Espinoza, Fernando López-Mozos, Roberto Marti-Obiol, Marina Garces-Albir, Joaquin Ortega-Serrano, Department of Digestive and General Surgery, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
Author contributions: All authors contributed equally to this work.
Institutional review board statement: Institutional Review Board’s approval is unnecessary for this manuscript, because of its retrospective character. Individual subjects cannot be identified in any way by the data collected.
Informed consent statement: Informed consent is unnecessary for this manuscript, because of its retrospective character. Individual subjects cannot be identified in any way by the data collected.
Conflict-of-interest statement: All authors declare having no conflicts of interest of any kind.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at garalma@hotmail.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marina Garces-Albir, MD, PhD, Department of Digestive and General Surgery, Hospital Clínico Universitario de Valencia, Avd. Blasco Ibañez, 17, 46010 Valencia, Spain. garalma@hotmail.com
Telephone: +34-96-2051717 Fax: +34-96-3868864
Received: March 22, 2016 Peer-review started: March 23, 2016 First decision: April 15, 2016 Revised: April 28, 2016 Accepted: May 17, 2016 Article in press: May 27, 2016 Published online: August 15, 2016 Processing time: 141 Days and 0.4 Hours
Abstract
AIM: To determine reproducibility of perioperative chemotherapy for gastric cancer (GC) on our settings by identifying patient’s overall survival and comparing them to larger studies.
METHODS: Retrospective analysis of our series, where we present our eleven-year’s experience on GC managed according to perioperative approach of three preoperative chemotherapy cycles followed by surgery and finally three postoperative chemotherapy cycles. Chemotherapic scheme used was Xelox (Oxaliplatin and Capecitabine). Epidemiologic parameters as well as surgical variables were analysed, presented, and compared to other series with similar approaches. Survival was estimated by Kaplan Meier/log rank method and also compared to these studies.
RESULTS: Mean age was 65 years old. Overall survival in our series was 37.7%, similar to other groups using perioperative schemes. Mortality was 4% and morbidity 30%, which are also similar to those groups. Survival curves were compared to larger studies, finding similarities on them. Subgroup survival analysis between chemotherapy responders and non-responders didn’t reach statically significant differences.
CONCLUSION: Perioperative chemotherapic scheme can be reproduced on our setting with good results and without increasing morbidity or mortality.
Core tip: This is a retrospective study that evaluates and compares survival after perioperative chemotherapy on gastric cancer patients managed similarly in other settings. We confirmed reproducibility of this scheme on smaller settings than classic studies.
